Myelogenous Leukemia, Acute Clinical Trial
Official title:
Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML).
This multi-center, open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of RO5429083 alone and in combination with cytarabine in patients with acute myelogenous leukemia. In Part A, patients will receive multiple escalating doses of RO5429083 intravenously. In Part B, patients will receive RO5429083 plus up to 4 cycles of cytarabine (1000 mg/m2 iv daily for 5 consecutive days). Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00374296 -
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
|
Phase 2 | |
| Active, not recruiting |
NCT02665065 -
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 3 | |
| Terminated |
NCT00907517 -
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
|
Phase 1 | |
| Completed |
NCT01635296 -
A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
|
Phase 1 | |
| Completed |
NCT01773408 -
A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
|
Phase 1 | |
| Completed |
NCT00130702 -
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
|
Phase 2 | |
| Recruiting |
NCT04989335 -
Bisantrene Combination for Resistant AML
|
Phase 2 |